Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NGN-101 by Neurogene for Batten Disease: Likelihood of Approval
NGN-101 is under clinical development by Neurogene and currently in Phase II for Batten Disease. According to GlobalData, Phase II...